SCHEMBL486431

SCHEMBL486431

Nc1ccc(CNC(=O)Nc2ccc(-c3ncc(C(=O)NCCN4CCCCC4)c(NC4CC4)n3)cc2F)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KIT P10721 1/20 0.40
TRPA1 O75762 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
NAMPT P43490 4/20 0.38
MERTK Q12866 6/20 0.38
TYRO3 Q06418 4/20 0.38
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
AXL P30530 1/20 0.38
IKBKB O14920 1/20 0.38
FLT3 P36888 3/20 0.37
GAS6 Q14393 3/20 0.37
TRPV1 Q8NER1 1/20 0.37
CASK O14936 1/20 0.37
BMPR1B O00238 1/20 0.37
BMPR1A P36894 1/20 0.37
TGFBR1 P36897 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL486114 0.91 MEN1 (0.41) MEN1KMT2AKITTRPA1IRAK4
SCHEMBL485922 0.90 KIT (0.42) MEN1KMT2AKITNAMPTIKBKB
SCHEMBL485943 0.89 ATR (0.43) MEN1KMT2AKITNAMPTTRPV1
SCHEMBL3719617 0.86 NAMPT (0.41) TRPA1NAMPTMERTKTYRO3AXL
SCHEMBL3717766 0.81 KIT (0.36) MEN1KMT2AKITNAMPTIKBKB
SCHEMBL3046675 0.80 NAMPT (0.46) KITIRAK4NAMPTMERTKTYRO3
SCHEMBL485895 0.80 PIK3CA (0.44) MEN1KMT2AKITNAMPTIKBKB
SCHEMBL485908 0.80 PIK3CA (0.41) MEN1KMT2AKITNAMPTIKBKB
SCHEMBL485903 0.80 PIK3CA (0.41) MEN1KMT2AKITNAMPTIKBKB
SCHEMBL485853 0.80 PIK3CA (0.41) MEN1KMT2AKITNAMPTIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-03-01 US claimed
EP-2411368-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-02-01 EP claimed
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-03-01 US disclosed
EP-2411368-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS NAMPT, NNT, NQO1 MEN1 560/4885KMT2A 2289/4885KIT 890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.